Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 3 | 2023 | 542 | 0.960 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2023 | 1193 | 0.940 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 35 | 0.850 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 123 | 0.810 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 145 | 0.800 |
Why?
|
| Fanconi Anemia | 1 | 2018 | 44 | 0.600 |
Why?
|
| alpha-Fetoproteins | 1 | 2018 | 131 | 0.570 |
Why?
|
| SOS1 Protein | 1 | 2016 | 1 | 0.560 |
Why?
|
| Noonan Syndrome | 1 | 2016 | 29 | 0.540 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 803 | 0.540 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2016 | 51 | 0.520 |
Why?
|
| Gene Duplication | 1 | 2016 | 358 | 0.480 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 258 | 0.450 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 678 | 0.430 |
Why?
|
| Interferon-gamma | 1 | 2015 | 511 | 0.430 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 474 | 0.410 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 28 | 0.220 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 141 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.210 |
Why?
|
| Recurrence | 1 | 2023 | 1419 | 0.170 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 293 | 0.160 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 334 | 0.140 |
Why?
|
| Transplantation Conditioning | 3 | 2023 | 323 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2016 | 119 | 0.130 |
Why?
|
| ras Proteins | 1 | 2016 | 136 | 0.130 |
Why?
|
| CD3 Complex | 1 | 2015 | 82 | 0.130 |
Why?
|
| CD40 Ligand | 1 | 2015 | 64 | 0.130 |
Why?
|
| CD28 Antigens | 1 | 2015 | 78 | 0.120 |
Why?
|
| Biological Assay | 1 | 2015 | 101 | 0.120 |
Why?
|
| Coculture Techniques | 1 | 2015 | 234 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 314 | 0.120 |
Why?
|
| Antibodies | 1 | 2015 | 370 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2023 | 15928 | 0.110 |
Why?
|
| Cell Survival | 1 | 2015 | 803 | 0.110 |
Why?
|
| Alemtuzumab | 2 | 2023 | 88 | 0.100 |
Why?
|
| Humans | 8 | 2023 | 122991 | 0.090 |
Why?
|
| Child | 4 | 2023 | 24144 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1870 | 0.090 |
Why?
|
| Cell Line | 1 | 2015 | 2779 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2023 | 13819 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2306 | 0.080 |
Why?
|
| Phenotype | 1 | 2016 | 4221 | 0.070 |
Why?
|
| Busulfan | 1 | 2023 | 44 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 26 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 49 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 657 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 98 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 295 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2021 | 82 | 0.050 |
Why?
|
| Rituximab | 1 | 2022 | 156 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 420 | 0.050 |
Why?
|
| Female | 2 | 2018 | 65304 | 0.050 |
Why?
|
| Hospitals | 1 | 2021 | 397 | 0.040 |
Why?
|
| Infant | 2 | 2023 | 12286 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1114 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1230 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 19030 | 0.030 |
Why?
|
| Aged | 2 | 2022 | 19033 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 3542 | 0.030 |
Why?
|
| Male | 1 | 2018 | 59898 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6022 | 0.030 |
Why?
|
| Young Adult | 1 | 2022 | 8840 | 0.020 |
Why?
|
| Middle Aged | 1 | 2022 | 25929 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 28978 | 0.010 |
Why?
|